Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Aurinia Pharmaceuticals (AUPH)
NASDAQ:AUPH
RESEARCH TOOLSreports
AUPH Stock Chart & Stats
Day’s Range― - ―
52-Week Range$4.71 - $10.67
Previous CloseN/A
Volume460.34K
Average Volume (3M)1.24M
Market Cap
$1.14B
Enterprise Value$806.73M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.43
Next Earnings
Mar 04, 2025EPS Estimate
0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.16
Shares Outstanding143,179,280
10 Day Avg. Volume1,061,193
30 Day Avg. Volume1,241,744
Standard Deviation0.22
R-Squared0.08
Alpha-0.00771
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)5.18
Price to Cash Flow (P/CF)16.80
P/FCF Ratio15.80
Enterprise Value/Market Cap0.71
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit5.00
Enterprise Value/Ebitda633.72
Forecast
1Y Price Target
$11.00Price Target Upside39.77% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering0
---
Aurinia Pharmaceuticals News
PremiumCompany Announcements
Aurinia Pharmaceuticals Celebrates New Lupus Nephritis Guidelines
PremiumCompany Announcements
Aurinia Highlights Lupus Nephritis Breakthroughs at ACR 2024
PremiumCompany Announcements
Aurinia Pharmaceuticals Engages at London Conference
PremiumCompany Announcements
Aurinia Pharmaceuticals Reports Strong Growth and Strategic Restructuring---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceAurinia reported 3Q-2024 results with total revenues beating estimates and consensus.
International ApprovalAurinia announced that the Japanese Health Authorities have approved Lupkynis for the treatment of lupus nephritis, which could lead to incremental revenues.
Treatment GuidelinesThe overall updated guidelines are seen as a net positive for the continued commercialization of Lupkynis.
Bears Say
Growth ConcernsEven with no growth quarter over quarter, the company should be able to roughly hit the mid-point of guidance.
Patent ProtectionThe longevity of the Lupkynis patent protection in the U.S. remains an uncertainty with maximum composition of matter patent term extension ending in October 2027.
Standalone StrategyAnalyst expresses disappointment that Aurinia will remain standalone, as more value could have been created with strategic synergies within a more established commercial organization.
---
Ownership Overview
8.71% Insiders
5.42% Mutual Funds
16.06% Other Institutional Investors
63.61% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
AUPH FAQ
What was Aurinia Pharmaceuticals’s price range in the past 12 months?
Aurinia Pharmaceuticals lowest stock price was $4.71 and its highest was $10.67 in the past 12 months.
What is Aurinia Pharmaceuticals’s market cap?
Aurinia Pharmaceuticals’s market cap is $1.14B.
When is Aurinia Pharmaceuticals’s upcoming earnings report date?
Aurinia Pharmaceuticals’s upcoming earnings report date is Mar 04, 2025 which is in 12 days.
How were Aurinia Pharmaceuticals’s earnings last quarter?
Aurinia Pharmaceuticals released its earnings results on Nov 07, 2024. The company reported $0.1 earnings per share for the quarter, beating the consensus estimate of $0.015 by $0.085.
Is Aurinia Pharmaceuticals overvalued?
According to Wall Street analysts Aurinia Pharmaceuticals’s price is currently Undervalued.
Does Aurinia Pharmaceuticals pay dividends?
Aurinia Pharmaceuticals does not currently pay dividends.
What is Aurinia Pharmaceuticals’s EPS estimate?
Aurinia Pharmaceuticals’s EPS estimate is 0.02.
How many shares outstanding does Aurinia Pharmaceuticals have?
Aurinia Pharmaceuticals has 143,179,280 shares outstanding.
What happened to Aurinia Pharmaceuticals’s price movement after its last earnings report?
Aurinia Pharmaceuticals reported an EPS of $0.1 in its last earnings report, beating expectations of $0.015. Following the earnings report the stock price went up 10.904%.
Which hedge fund is a major shareholder of Aurinia Pharmaceuticals?
Currently, no hedge funds are holding shares in AUPH
---
Aurinia Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$11.00 (39.77% Upside)
$11.00 (39.77% Upside)
Blogger Sentiment
Bullish
AUPH Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Bought Shares
Worth $10.8M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▲ 0.3%
Last 30 Days ▲ 0.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
34.52%
12-Months-Change
Fundamentals
Return on Equity
-5.78%
Trailing 12-Months
Asset Growth
-1.02%
Trailing 12-Months
Company Description
Aurinia Pharmaceuticals
Aurinia Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of a therapeutic drug to treat autoimmune diseases particularly lupus nephritis. The company was founded by Robert Foster, Richard Glickman and Michael Martin on June 16, 1993 and is headquartered in Victoria, Canada.
---
AUPH Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted strong revenue growth and strategic progress, including significant milestones in product approvals and R&D. However, the restructuring and substantial workforce reduction indicate underlying challenges in operational efficiency and cost management, balancing the positive aspects.Read More>---
AUPH Revenue Breakdown
90.00% U.S.
10.00% Japan
---
AUPH Stock 12 Month Forecast
Average Price Target
$11.00
▲(39.77% Upside)
Technical Analysis
Best Analysts Covering AUPH
1 Year
1 Year Success Rate
12/21 ratings generated profit
1 Year Average Return
+29.98%
reiterated a buy rating 3 months ago
Copying David Martin PhD's trades and holding each position for 1 Year would result in 57.14% of your transactions generating a profit, with an average return of +29.98% per trade.
---